Charlotte Aaquist Haslund on Muck Rack

Charlotte Aaquist Haslund

As seen in: European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Charlotte Aaquist

Contact Charlotte Aaquist, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

|
By Eva Ellebæk, Lars Bastholt, Marco Donia, Charlotte Aaquist Haslund
| European Journal of Cancer Verified
Highlights • PD-L1≥1% is an independent positive prognostic biomarker in metastatic melanoma • PD-L1≥1% did not derive additional benefit from anti-CTLA-4 over anti-PD-1 alone • Combination therapy demonstrated improved PFS only in patients with PD-L1<1% Abstract Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified